Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach.
High-grade gliomas are the most common primary malignant brain tumours. Surgery, radiotherapy and chemotherapy are the cornerstone of actual treatment. In spite of large therapeutic efforts, overall survival is still poor. New molecular data allow a new molecular classification for high-grade gliomas and open a therapeutic window for targeted therapy. Molecular diagnostic tools may provide a basis for receptor-based therapies and enough information to personalise future treatments. In this regard, epidermal growth factor receptor (EGFR) is a target that will play a critical role in the management of glioma patients. This review summarises basic and preclinical data that support future use of therapies against EGFR.
Belda-Iniesta
Cristóbal
C
Translational Oncology Unit (CSIC/UAM) at Medical Oncology Division, University Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain. cbelda@iib.uam.es
de Castro Carpeño
Javier
J
Sereno
María
M
González-Barón
Manuel
M
Perona
Rosario
R
D000818:Animals; D001932:Brain Neoplasms / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D005909:Glioblastoma / Q000378:metabolism*; D006801:Humans
D066246:ErbB Receptors